ストックスクリーナーアプリを入手
34.69
0.32%
-0.11
Teva Pharmaceutical Industries Ltd Adr (TEVA) 最新ニュース
Harel Insurance Sold $330 Million of Invesco KBW Bank ETF - The Motley Fool
Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat - Finviz
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory - Finviz
Teva Canada Mayzent Deal Supports Neuroscience Focus And Valuation Debate - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Earnings call transcript: Teva Q4 2025 earnings beat expectations, stock rises - Investing.com
Assessing Teva Pharmaceutical Industries’ Valuation After Strong 2025 Earnings And Analyst Upgrades - Sahm
Teva (TEVA) Is Up 7.1% After 2025 Earnings Highlight Branded-Drugs Momentum And Pipeline Progress - Sahm
Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds - Finviz
Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis - Finviz
Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 92% One-Year Share Price Surge - Sahm
Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 12-Month High Following Earnings Beat - Defense World
Teva Balances Huntington’s Disease Outreach With Branded Drug Transformation - Sahm
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
What Makes Teva Pharmaceuticals (TEVA) a Successful Brand? - Finviz
Teva Pharma stock hits 52-week high at 33.42 USD By Investing.com - Investing.com Nigeria
Teva Pharma stock hits 52-week high at 33.42 USD - Investing.com
Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Margin Recovery Challenges High P/E Valuation Narrative - Sahm
Teva To See Generics Loss From Revlimid in 2026, but Innovative Portfolio Drives Margin Expansion - morningstar.com
Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook - Sahm
Earnings call transcript: Teva beats Q4 2025 EPS forecast, stock dips - Investing.com
Assessing Teva (TEVA) Valuation As Guidance Driven Momentum Lifts Long Term Profit Expectations - Sahm
The Truth About Teva Pharmaceutical (ADR): Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results? - Finviz
Sodium Chloride Injections Market, Global Forecast 2026-2032 - GlobeNewswire Inc.
This pharma stock “is beating everything”, investor says - Cantech Letter
How Long-Term Profit Targets and TEV-‘408 Funding At Teva Pharmaceutical (TEVA) Has Changed Its Investment Story - Sahm
Is Teva (TEVA) Still Reasonably Priced After A 195% Three Year Share Price Gain - Sahm
Assessing Teva Pharmaceutical Industries (TEVA) Valuation After A Sharp Multi‑Month Share Price Rally - Sahm
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Finviz
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug - Sahm
Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32 - Finviz
Should Teva’s Q3 Beat and New Schizophrenia and Denosumab Moves Require Action From TEVA Investors? - Sahm
Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 49% One Year Share Price Jump - Sahm
Teva stock hits 52-week high at $32.02 - Investing.com
Teva Pharmaceutical Industries (NYSE:TEVA): Assessing Valuation After a 46% Share Price Rebound - Sahm
Top 2 Health Care Stocks That May Crash In Q1 - Sahm
Teva Pharmaceutical (ADR) Is Popping Off: Smart Buy or Overhyped Trap? - AD HOC NEWS
Teva Pharmaceutical (ADR): Bracing For 2026 After A Volatile Year Of Legal Wins, Debt Cuts And A Re- - AD HOC NEWS
The Truth About Teva Pharmaceutical (ADR): Is Wall Street Sleeping on This Comeback Play? - AD HOC NEWS
The Truth About Teva Pharmaceutical (ADR): Is This ‘Boring’ Stock Quietly Going Viral with Inves - AD HOC NEWS
What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)? - Finviz
Has Teva’s Surging Share Price Outpaced Its Long Term Recovery Prospects? - Sahm
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive - Sahm
J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play - Finviz
Teva Pharma stock hits 52-week high at 30.45 USD By Investing.com - Investing.com Australia
Teva Pharma stock hits 52-week high at 30.45 USD - Investing.com India
Teva (TEVA): Assessing Valuation After a 65% Three‑Month Share Price Surge - Sahm
BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight - Finviz
1.10%
大文字化:
|
ボリューム (24 時間):